S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
The “Perfect Storm” for Gold (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
How to Know Which AI Company to Invest In… and When (Ad)
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
Free Trial
NASDAQ:NLSP

NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)
Free NLSP Stock Alerts
$0.14
0.00 (-3.18%)
(As of 05:32 PM ET)
Compare
Today's Range
$0.13
▼
$0.15
50-Day Range
$0.14
▼
$0.50
52-Week Range
$0.13
▼
$1.58
Volume
278,611 shs
Average Volume
491,936 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
NLSP stock logo

About NLS Pharmaceutics Stock (NASDAQ:NLSP)

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLSP Stock Price History

NLSP Stock News Headlines

April 7, 2024 | americanbankingnews.com
Flora Growth (NASDAQ:FLGC) vs. NLS Pharmaceutics (NASDAQ:NLSP) Critical Survey
March 22, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
April 16, 2024 | Gold Safe Exchange (Ad)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
March 20, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
March 20, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
March 14, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
March 11, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
March 11, 2024 | finance.yahoo.com
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
April 16, 2024 | Gold Safe Exchange (Ad)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
February 23, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
February 14, 2024 | seekingalpha.com
NLSP NLS Pharmaceutics Ltd.
January 20, 2024 | finance.yahoo.com
Notice of Deficiency with Nasdaq Continued Listing Requirements
January 12, 2024 | finanznachrichten.de
NLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing Requirements
December 23, 2023 | benzinga.com
NLS Pharmaceutics Stock (NASDAQ:NLSP) Insider Trades
December 21, 2023 | morningstar.com
NLS Pharmaceutics Ltd Ordinary Shares
December 5, 2023 | benzinga.com
NLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and Dates
December 1, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
November 27, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
November 21, 2023 | morningstar.com
NLS Pharmaceutics Ltd Ordinary Shares NLSP
November 16, 2023 | msn.com
Why NLS Pharmaceutics (NLSP) Stock Is Down 40% Today
November 16, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
October 19, 2023 | finance.yahoo.com
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
October 12, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic Partnerships
October 12, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
October 5, 2023 | msn.com
NLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95
September 14, 2023 | msn.com
Maxim Group Downgrades NLS Pharmaceutics (NLSP)
August 28, 2023 | benzinga.com
NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
See More Headlines
Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/16/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NLSP
CUSIP
N/A
CIK
1783036
Web
www.nlspharma.com
Phone
41-44-512-2150
Fax
41-41-618-8009
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
0.48

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.82
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Alexander Zwyer M.B.A. (Age 55)
    President, CEO & Director
    Comp: $1.07M
  • Dr. George Apostol M.D. (Age 51)
    Chief Medical Officer and Global Head of Research & Development
    Comp: $154k
  • Dr. Eric Konofal M.D. (Age 57)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Ms. Elena Thyen-Pighin
    Chief Financial Officer
  • Dr. Christian C. Wenger Dr. iur. (Age 60)
    L.L.M., Ph.D., General Counsel

Key Competitors

View All Competitors

NLSP Stock Analysis - Frequently Asked Questions

Should I buy or sell NLS Pharmaceutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NLSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLSP, but not buy additional shares or sell existing shares.
View NLSP analyst ratings or view top-rated stocks.

How have NLSP shares performed in 2024?

NLS Pharmaceutics' stock was trading at $0.5899 at the start of the year. Since then, NLSP stock has decreased by 76.8% and is now trading at $0.1370.
View the best growth stocks for 2024 here.

Are investors shorting NLS Pharmaceutics?

NLS Pharmaceutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 335,800 shares, an increase of 854.0% from the March 15th total of 35,200 shares. Based on an average daily volume of 531,500 shares, the short-interest ratio is currently 0.6 days. Approximately 1.5% of the company's shares are sold short.
View NLS Pharmaceutics' Short Interest.

When is NLS Pharmaceutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our NLSP earnings forecast.

When did NLS Pharmaceutics IPO?

NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLSP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
You won't believe what Citigroup just did to it's depositors
American Alternative
Options trading has suddenly become more reliable.
Eagle Publishing